This is a multicenter randomized phase ll clinical trial to evaluate the pathological
complete response (pCR) in the tumour burden (primary and lymph nodes) with olaparib alone or
in the olaparib and durvalumab arm in TNBC patients candidate for neoadjuvant strategy
showing a t/gBRCAmut or BRCAness/HRD profile.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC